Decitabine (also referred to as Dacogen or 5-aza-2'-deoxycytidine) is a drug that has recently been FDA-approved for the treatment of myelodysplastic syndrome (MDS). The mechanism of action is believed to be the blocking of DNA methylation and thereby reactivating silenced genes 
Paradoxically though, Myc also triggers apoptosis 1, 2 which is a cellular defense against cancer.
For that reason, mutations in genes governing or executing apoptotic pathways are always accompanying Myc mutations in tumors 3 .
The tumor suppressor p53 is crucial in the defense against activated Myc oncogenes and it can be activated in two major ways; one pathway involving the Arf tumor suppressor and one involving the upstream kinases of the DNA damage response (DDR), ATM/ATR and DNA-PK. How Myc induces Arf 4 is not completely understood but when it does, Arf inhibits the E3 ubiquitin ligase Mdm2 which is a transcriptional target of p53 and acts as its negative regulator 5 .
By inhibiting Mdm2, Arf causes p53 accumulation, resulting in the activation of genes downstream of p53 such as those encoding the cell cycle inhibitor p21, DNA repair proteins or pro-apoptotic proteins of the Bcl-2 family like Noxa and Puma 5 . A similar scenario is the end result of Myc activating a DDR where unscheduled Myc-induced replication causes strand breaks leading to activation of ATM, ATR or DNA-PK 6 . Downstream of these are the Chk1/2 kinases which regulates the phosphorylation of cyclin:Cdk complexes to transiently arrest cells in the S and G2 phases of the cell cycle. They also phosphorylate p53 which disrupts the For personal use only. on October 3, 2017 . by guest www.bloodjournal.org From interaction with Mdm2 resulting in p53 activation and a more prolonged arrest 7 . Importantly, however, since high levels of Myc can repress p21 gene transcription 8, 9 , the outcome of p53 activation by both the Arf and the DDR pathways in the context of Myc overexpression tips the balance towards apoptosis rather than cell cycle inhibition 8, 10 . This may explain why oncogeneinduced senescence seen in many precancerous lesions is rarely seen in Myc-induced tumors but may be triggered when Myc itself is inactivated 11 .
Genetic studies in mice have shown that the pathways triggering p53 described above are essential for keeping Myc in check but they are not mutually exclusive. For instance, inactivation of Arf or Atm in Myc-transgenic mice that normally develops B-cell lymphoma (e.g.
Eµ-Myc mice) results in a dramatic acceleration of disease but inactivation of p53 is even more deleterious, suggesting that both Arf and DDR pathways are important [12] [13] [14] [15] . Interestingly, analyses of B-cell lymphomas that develop in Myc-transgenic mice and in the human disease Burkitt lymphoma (BL), where Myc is overexpressed in B lymphocytes because of translocation of MYC to any of the three immunoglobulin-encoding loci, have shown that Arf and p53 mutations occur spontaneously during tumor development 12, 13, 16, 17 . Besides p53, other genes such as members of the Bcl-2 family are also implicated as regulators of Myc-induced apoptosis 3 .
Methylation of cytosines in CpG sequences of promoter regions is commonly observed during tumor progression to inactivate genes whose products are important for processes such as DNA repair, cell cycle regulation, cell adhesion, angiogenesis and apoptosis 18 For personal use only. on October 3, 2017. by guest www.bloodjournal.org From Apoptosis was determined using DNA histograms on PI-stained cells (as above) and was based on the number of cells which carried one log less than diploid DNA content (sub-G1) in the FL2 channel in a logarithmic scale. Apoptosis was also measured by flow cytometry using Annexin V conjugated to R-phycoerythrin (PE; BD Biosciences) which labels phosphatidylserine that flips to the outside of apoptotic cells, and 7-aminoactinomycin D (7-AAD; Sigma) which labels DNA, as per BD Biosciences' recommendation.
Western blot analysis. Cell pellets or tumors crushed in liquid nitrogen were lysed essentially as described before 4 . Protein was separated on SDS-PAGE gels and subsequently transferred to nitrocellulose membranes. Antibody staining was carried out in TBS-Tween and antibody binding was visualized by enhanced chemiluminescence using SuperSignal from Pierce.
RNA preparation and analysis. RNA from cultured cells was isolated using Trizol reagent (Invitrogen). cDNA synthesis was performed on 1 µg RNA using iScript first strand synthesis kit (Bio-Rad). qRT-PCR was performed using the SYBRgreen PCR mastermix (Biotools), cDNA and primers directed against Puma (human), caspase-2 (mouse) and Ubiquitin (Ub; human and mouse) on an IQ real-time PCR machine (Bio-Rad). Relative mRNA levels were calculated using the ΔΔCT method, comparing expression of Puma or caspase-2 with that of Ub. 
Results

Decitabine causes aneuploidy and cell death in Burkitt lymphoma (BL) cells carrying mutations in TP53.
Previous studies have shown that loss of the pro-apoptotic BH3-only protein Puma accelerates Myc-induced B-cell lymphomagenesis in mice and that a selection against Puma expression occurs in BL of humans 27, 28 . In BL, methylation of the PUMA gene was observed in many primary tumors and cell lines, correlating with low expression of Puma.
Treatment of these lines with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine (Decitabine) caused a reactivation of Puma expression, demonstrating that methylation was needed for PUMA gene silencing 28 . We wanted to evaluate if Puma reactivation was the sole cause of the apoptosis that results from Decitabine treatment of KemI and Akata BL cells, which both exhibit PUMA methylation. By using lentiviruses carrying shRNA directed against PUMA we were able to knockdown the expression of Puma RNA and protein in the Akata cell line (Supplemental Figure 1A and 1B). Interestingly, Puma knockdown reduced the level of caspase-9 activation and Annexin V positivity, hallmarks of the mitochondrial apoptosis regulated by Puma 29 , but it did not prevent cell death completely and in long term experiments it had no effect at all (Supplemental Figure 1B and 1C, and data not shown). Therefore, Puma is in part a mediator of the apoptotic response to Decitabine but Puma-independent death is also involved.
To gain more insight into Decitabine-induced cell death in BL cells we analyzed these cells by FACS to produce DNA histograms. One of the most striking things noted besides the considerable sub-G1 population that had accumulated 48 h after Decitabine treatment, was the appearance of cells carrying much higher than 4N content ( Figure 1A ), indicative of aneuploidy. 33 . Although the mouse lymphoma lines also exhibited aneuploidy, indicating that this feature can occur independently of the human-specific EBV, we reasoned that the virus may still play a role in potentiating aneuploidy in the human cells which were devoid of p53 function. We therefore analyzed the expression of some of the EBV genes that have been shown to be induced by Decitabine and whose products may exert a function in regulating apoptosis or aneuploidy.
Decitabine-induced cell death and aneuploidy does not only occur in EBV-
Surprisingly, although the mRNA encoding the master transcriptional regulator EBNA-2 and its downstream target genes LMP-1, LMP-2 and ZEBRA (BZLF-1) were all induced by Decitabine at the time point when aneuploidy is observed, only ZEBRA was induced to protein levels similar to Raji and KemIII which express a EBV latency III program (Supplemental Figure 3A and B).
Decitabine causes a transient G2 arrest in Burkitt lymphoma (BL) cells with mutations in
TP53.
To set the stage for aneuploidy we reasoned that one or several checkpoints had been overridden. Indeed, by analyzing Akata cells 24 hours after Decitabine administration an enrichment of cells arrested in the G2/M phase was observed which was dissolved at 48 hours correlating with aneuploidy or cell death ( Figure 2A ). This is an event that very often can be seen in p53-deficient cells subjected to DNA damage, since in normal cells p53 and its downstream target p21 are dispensable for the rapid Chk1 and Chk2-mediated arrest but responsible for the prolonged G2 arrest [35] [36] [37] . We therefore investigated if DNA damage by γ-IR treatment of Akata cells would result in a similar cell cycle profile as Decitabine treatment. The kinetics were far from identical, which is not surprising since γ-IR treatment results in an immediate DNA damage
whereas Decitabine requires incorporation into DNA, but the basic events were similar, both treatments caused an arrest followed by aneuploidy or cell death. Using a flow cytometry method that is based on the fact that the nuclear envelope is disintegrated at mitosis causing a drop in granularity (side-scatter) of the cells 24 , we were able to show that the transient arrest of Akata cells upon γ-IR or Decitabine treatment was in G2 and not in M ( Figure 2B ).
Decitabine elicit a DNA damage response (DDR). Previous studies have shown that Decitabine
can induce effects other than DNA hypomethylation, including DNA damage 38, 39 . Thus, we sought to determine if a DNA damage response (DDR) was triggered in KemI and Akata cells that lack functional p53. Phosphorylation of histone H2AX (γ-H2AX) is one of the earliest and most reliable markers for an activated DDR 40 and it is carried out by the proximal kinases ATM and ATR. γ-H2AX can be detected by immunofluorescence as foci at the site of lesion in the nucleus of damaged cells. We observed elevated levels of γ-H2AX in Akata ( Figure 2C and Supplemental Figure 4C ) and KemI (not shown) cells by using immunofluorescence which was confirmed by Western blot analysis. Moreover, to further confirm that a DDR was elicited by
Decitabine we also analyzed the phosphorylation status of p53 as a surrogate marker for an activated DDR. As seen in Figure 2D , serine 15 of p53 was strongly phosphorylated in KemI and 
org From
Myc is a sensitizer to Decitabine. The KemI and Akata cells used in this study have been in culture for many decades so it was of interest to set up a system of primary cultures to see if we could mimic the effects with a minimal amount of genetic lesions. We utilized early-passage p53 deficient mouse embryo fibroblasts (MEFs) which were found to be sensitive to Decitabine, but not as sensitive as the BL lines. We therefore transduced p53 -/-MEFs with a control retrovirus (MSCV-IRES-puro) or one engineered to express a conditionally active form of c-Myc, the Figure 3B) . Thus, the results show that it is not only loss of p53 function that sensitizes BL cells to DNA damage by Decitabine but also the active MYC oncogene.
To gain insight into the mechanism behind the checkpoint override by Myc and the ensuing apoptosis we entertained the following option: Chk1 is activated by DNA damage Figure 3C ). This transient endurance of phosphorylated Cdc2 upon Decitabine-induced DDR was also confirmed in Akata cells ( Figure 3D ). Figure 5A) which has also been seen in another Myc-induced cancer model, the Eµ-Myc mouse 12, 13 . The tumors that developed were Myc-expressing B-cell lymphomas (B220+) that had infiltrated many lymphoid organs such as spleen, bone marrow and lymph nodes and they were either IgM positive or negative as previously reported for the parental iMyc Eµ mouse model 25 ( Figure 5D and Supplemental Figure 6A and B). Western blot analysis showed that the p53 protein was either lost (LOH) or elevated, indicative of a de novo mutation ( Figure 5B ). Tumors with compromised p53 function were transplanted into recipient C57/BL6 mice to create colonies of mice that developed the same disease as the donor mouse within 3-4 weeks. The colonies were divided into groups that were either left untreated or treated one week after transplantation with Decitabine. Interestingly, Decitabine showed very potent efficacy with just three injections during 24 h ( Figure 5C ) delaying tumor onset from 23 to 34 days (p=0.0009). We were also able to cause remission in mice that were injected with Decitabine on the day the mice showed signs of palpable lymphoma (data not shown) but the tumors relapsed eventually in all mice. The tumors that arose were not secondary tumors arising because of Decitabine treatment but were Myc-expressing B-cell lymphomas like the original tumors ( Figure 5D ).
Myc sensitizes cells to Decitabine by inducing cell death pathways that involves caspases.
As shown above, p53 deficient mouse and human tumor cells are sensitive to
Decitabine but are they more sensitive than cells with functional p53? To test this we decided to inhibit p53 function with the p53 inhibitor pifithrin-α (PFTα) 46 For
Discussion
Patients suffering from BL are often responsive to chemotherapy despite the fact that these tumors frequently carry TP53 mutations. Based on our previous study 10 , and data presented herein, we would argue that this responsiveness is due to the combined over-activity of the MYC oncogene, p53 loss and DNA damage which leads to several different types of cell death. Since
Decitabine has potential to both demethylate genes and induce DNA damage, perhaps introduction of Decitabine and thereby replacing some DNA damaging drugs in anti-cancer regimes will result in improved treatment responses of Myc-induced cancers such as leukemia/lymphoma, colon, prostate and breast cancer.
The in vitro findings presented here extend and confirm c-Myc's cell cycle effects to include not only S-phase progression but also the transition through the G2 and M phases. This is a less appreciated role of c-Myc which in the case of cancer cells may play dual and opposite roles; to enhance aneuploidy leading to transformation and to sensitize the transformed cells to DNA damaging drugs that enforce an arrest in these cell cycle phases. Myc was recently shown to have an inhibitory role in pro-metaphase by transactivating the mitotic regulators BubR1 and MAD2, which was linked to Myc's propensity to trigger aneuploidy 44 DNA damage sensitizes p53 deficient cells to many types of cell death including PARP-mediated necrosis 49 , mitotic catastrophe and caspase-independent mitotic death (CIMD).
The latter was recently shown to involve mitochondrial release of Apoptosis-inducing factor and Endonuclease G which resulted in DNA fragmentation independent of caspases 50 , similar to what we observed in the mouse lymphoma cells. If Decitabine triggers CIMD or other types of caspase-independent deaths then Akata cells must have developed resistance against this alternative form of cell death during the decades it has been in culture world-wide since the pancaspase inhibitor protected these cells from Decitabine. We thus favor an expanded investigation of pathways involved in Decitabine-induced death since this is likely to be important in clinical related issues such as prediction and prevention of relapses. These studies will be important in order to optimize future usage of Decitabine in the clinic. For personal use only. on October 3, 2017. by guest www.bloodjournal.org From
